PARP1 and ovarian carcinoma: Such is the mechanistic basis for the potential synergy between antiangiogenics and PARP inhibitors, which has since been demonstrated in platinum-sensitive recurrent ovarian cancer for the cediranib–olaparib and the niraparib–bevacizumab combinations.12, 13, 14 As monotherapies, PARP inhibitors and antiangiogenics targeting vascular endothelial growth factor (VEGF) and the VEGF receptor (VEGFR) signalling pathways have both demonstrated antitumour activity in platinum-resistant and/or recurrent ovarian cancers.7